Cargando…

Dual‐Specificity Phosphatase 9 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through ASK1 Suppression

Nonalcoholic fatty liver disease (NAFLD), ranging from nonalcoholic fatty liver to nonalcoholic steatohepatitis (NASH), is the leading cause of chronic liver diseases. Until now, no medications for NAFLD have been approved by relevant governmental agencies. Dual‐specificity phosphatase 9 (Dusp9) is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Ping, Xiang, Mei, Liao, Hua, Liu, Jijun, Luo, Hongbo, Wang, Yayun, Huang, Ling, Chen, Manhua, Xia, Jiahong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590435/ https://www.ncbi.nlm.nih.gov/pubmed/30063256 http://dx.doi.org/10.1002/hep.30198

Ejemplares similares

Dual-specificity Phosphatase 9 protects against Cardiac Hypertrophy by targeting ASK1
por: Jiang, Lang, et al.
Publicado: (2021)

Dual‐Specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through Transforming Growth Factor Beta–Activated Kinase 1 Suppression
por: Ye, Ping, et al.
Publicado: (2019)

Dual‐Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1
por: Zhao, Jing, et al.
Publicado: (2021)

microRNA-491-5p protects against atherosclerosis by targeting matrix metallopeptidase-9
por: He, Zhonghan, et al.
Publicado: (2020)

B-cell lymphoma 6 alleviates nonalcoholic fatty liver disease in mice through suppression of fatty acid transporter CD36
por: Zhang, Hao, et al.
Publicado: (2022)

Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis
por: Challa, Tenagne D, et al.
Publicado: (2019)

Protective effect of phytoestrogens on nonalcoholic fatty liver disease in postmenopausal women
por: Zhao, ChenLu, et al.
Publicado: (2023)

Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1
por: Qian, Qiaofeng, et al.
Publicado: (2022)

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
por: Loomba, Rohit, et al.
Publicado: (2017)

Reduced Glutathione suppresses Oxidative Stress in Nonalcoholic Fatty Liver Disease
por: Irie, Makoto, et al.
Publicado: (2016)

A Model Incorporating Serum Alkaline Phosphatase for Prediction of Liver Fibrosis in Adults with Obesity and Nonalcoholic Fatty Liver Disease
por: Ali, Ahmad Hassan, et al.
Publicado: (2021)

Protective effect of whey proteins against nonalcoholic fatty liver in rats
por: Hamad, Essam M, et al.
Publicado: (2011)

Protective role of arnebin-1 in rats with nonalcoholic fatty liver disease
por: Yang, Weijia, et al.
Publicado: (2019)

The Potential Protective Role of RUNX1 in Nonalcoholic Fatty Liver Disease
por: Bertran, Laia, et al.
Publicado: (2021)

Fentanyl Ameliorates Severe Acute Pancreatitis-Induced Myocardial Injury in Rats by Regulating NF-κB Signaling Pathway
por: Wang, Yayun, et al.
Publicado: (2017)

The Role of Bone Morphogenetic Protein 9 in Nonalcoholic Fatty Liver Disease in Mice
por: Sun, Qin-Juan, et al.
Publicado: (2021)

ASK “to be, or not to be?”
por: Okazaki, Tomohiko
Publicado: (2015)

Asked for It
Publicado: (1915)

Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease
por: Ran, Li-Sha, et al.
Publicado: (2022)

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease
por: Dongiovanni, Paola, et al.
Publicado: (2018)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease
por: Bebawi, Emmanuel, et al.
Publicado: (2023)

Cinnamic Acid Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Hepatic Lipogenesis and Promoting Fatty Acid Oxidation
por: Wu, You, et al.
Publicado: (2021)

Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA
por: Lee, Yo Han, et al.
Publicado: (2021)

Thrap3 promotes nonalcoholic fatty liver disease by suppressing AMPK-mediated autophagy
por: Jang, Hyun-Jun, et al.
Publicado: (2023)

Suppression of Dual Specificity Phosphatase I Expression Inhibits Hepatitis C Virus Replication
por: Choi, Jung Eun, et al.
Publicado: (2015)

Expression of Dual-Specificity Phosphatase 9 in Placenta and Its Relationship with Gestational Diabetes Mellitus
por: Wei, Qiang, et al.
Publicado: (2019)

Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease
por: Younossi, Zobair M., et al.
Publicado: (2017)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice
por: Rom, Oren, et al.
Publicado: (2019)

Asking and Receiving
por: Merivale, H.
Publicado: (1888)

Ask the Children
Publicado: (1950)

Askings and Answers
Publicado: (1884)

Deworming and Development: Asking the Right Questions, Asking the Questions Right
por: Bundy, Donald A. P., et al.
Publicado: (2009)

The art of asking: ask better questions, get better answers
por: Fadem, T J
Publicado: (2009)

Protective Effects and Mechanism of Meretrix meretrix Oligopeptides against Nonalcoholic Fatty Liver Disease
por: Huang, Fangfang, et al.
Publicado: (2017)

Pharmacological Effects and Molecular Protective Mechanisms of Astragalus Polysaccharides on Nonalcoholic Fatty Liver Disease
por: Zhang, Jing, et al.
Publicado: (2022)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Probiotics and Nonalcoholic Fatty liver Disease
por: Eslamparast, Tannaz, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hda61rsr7famgehdq2df8uhv06